Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors
J. Du, S. Meile, J. Baggenstos, T. Jaeggi, P. Piffaretti, L. Hunold, C. I. Matter, L. Leitner, T. M. Kessler, M. J. Loessner, S. Kilcher, M. Dunne
This paper develops heterologous effector phage therapeutics (HEPTs) to enhance bacteriophage treatment of UTIs by delivering colicin-like effectors that suppress resistance and improve bacterial killing.
bioRxiv · Mar 9, 2022 · PreprintBioengineering